International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Open accessAbstract
Key Points: Azacitidine increased median overall survival by 3.8 months vs current commonly used AML treatments (10.4 vs 6.5 months; P = .1009). Azacitidine safety in patients age ≥65 years with AML (>30% blasts) was consistent with its known safety profile in other trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The prolonged time to initial response, typically around 3 months from treatment onset, is consistent with the primary effects of low dose treatment being mediated via DNA demethylation and epigenetic reprogramming as opposed to direct cytotoxicity.
“The prolonged time to initial response, which typically occurs around 3 months from treatment onset 125 , is consistent with the primary effects of low dose treatment being mediated via DNA demethylation and epigenetic reprogramming as opposed to direct cytotoxicity 126-128 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,348 · see citing works
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686 · see citing works
Self-citationFenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · see citing works
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137 · see citing works
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,352 · see citing works
Kantarjian, H. M., Thomas, X., Dmoszyńska, A., Wierzbowska, A., Mazur, G. J., Mayer, J., Gau, J., Chou, W., Buckstein, R. J., Čermák, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,170 · see citing works
Self-citationFenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961 · see citing works
Self-citationBurnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619 · see citing works
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608 · see citing works
Survival for older patients with acute myeloid leukemia: a population-based study
Oran, B., & Weisdorf, D. J. (2012) · Haematologica · doi:10.3324/haematol.2012.066100 · Cited by 423 · see citing works
Kantarjian, H. M., Ravandi, F., O'Brien, S. M., Cortes, J. E., Faderl, S. H., Garcia‐Manero, G., Jabbour, E. J., Wierda, W. G., Kadia, T. M., Pierce, S. A., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276485 · Cited by 403 · see citing works
Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S. A., Daver, N. G., Garcia‐Manero, G., Faderl, S. H., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480228 · Cited by 381 · see citing works
Incidence, survival and prevalence of myeloid malignancies in Europe
Visser, O. J., Trama, A., Maynadié, M., Stiller, C. A., Marcos‐Gragera, R., Angelis, R. D., Mallone, S., Ţereanu, C., Allemani, C., Ricardi, U., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.024 · Cited by 195 · see citing works
Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1846.1846 · Cited by 183 · see citing works
Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
Korn, E. L., Freidlin, B., & Abrams, J. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6056 · Cited by 145 · see citing works
Gore, S. D., Fenaux, P., Santini, V., Bennett, J. M., Silverman, L. R., Seymour, J. F., Hellström‐Lindberg, E., Swern, A. S., Beach, C. L., & List, A. F. (2013) · Haematologica · doi:10.3324/haematol.2012.074831 · Cited by 135 · see citing works
Self-citationSantini, V., Fenaux, P., Mufti, G. J., Hellström‐Lindberg, E., Silverman, L. R., List, A. F., Gore, S. D., Seymour, J. F., Backstrom, J. T., & Beach, C. L. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01456.x · Cited by 133 · see citing works
Self-citationBurnett, A. K., Russell, N. H., Hunter, A., Milligan, D. W., Knapper, S., Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496596 · Cited by 132 · see citing works
Seymour, J. F., Fenaux, P., Silverman, L. R., Mufti, G. J., Hellström‐Lindberg, E., Santini, V., List, A. F., Gore, S. D., Backstrom, J. T., McKenzie, D., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.005 · Cited by 117 · see citing works
Self-citationAzacitidine in untreated acute myeloid leukemia: A report on 149 patients
Thépot, S., Itzykson, R., Seegers, V., Récher, C., Raffoux, E., Quesnel, B., Delaunay, J., Cluzeau, T., Marfaing‐Koka, A., Stamatoullas, A., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23654 · Cited by 101 · see citing works
Self-citationPleyer, L., Burgstaller, S., Girschikofsky, M., Linkesch, W., Stauder, R., Pfeilstöcker, M., Schreder, M., Tinchon, C., Sliwa, T., Lang, A. H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2126-9 · Cited by 97 · see citing works
Tan, P., Wei, A. H., Mithraprabhu, S., Cummings, N. J., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.68 · Cited by 95 · see citing works
Treatment of acute myeloid leukemia: are we making progress?
Burnett, A. K. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.1.3797038 · Cited by 89 · see citing works
Pollyea, D. A., Kohrt, H. E. K., Gallegos, L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.294 · Cited by 87 · see citing works
Pollyea, D. A., Zehnder, J. L., Coutre, S. E., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O. I., Greenberg, P. L., Zhang, B. M., Liedtke, M., Berube, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.076414 · Cited by 65 · see citing works
Pleyer, L., Stauder, R., Burgstaller, S., Schreder, M., Tinchon, C., Pfeilstöcker, M., Steinkirchner, S., Melchardt, T., Mitrovic, M., Girschikofsky, M., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-32 · Cited by 61 · see citing works
Acute Myeloid Leukemia in the Elderly
Dombret, H., Raffoux, E., & Gardin, C. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.013 · Cited by 58 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900 · see citing works
Self-citationDiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825 · see citing works
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778 · see citing works
Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692 · see citing works
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509 · see citing works
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220 · see citing works
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204 · see citing works
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151 · see citing works
Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30182-0 · Cited by 120 · see citing works
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102 · see citing works
Zeidan, A. M., Wang, R., Wang, X., Shallis, R. M., Podoltsev, N. A., Bewersdorf, J. P., Huntington, S. F., Neparidze, N., Giri, S., Gore, S. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001779 · Cited by 93 · see citing works
Craddock, C. F., Houlton, A. E., Quek, L. S., Ferguson, P., Gbandi, E., Roberts, C., Metzner, M., Garcia-Martin, N., Kennedy, A., Hamblin, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1423 · Cited by 88 · see citing works
Self-citationThe European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81 · see citing works
“Moreover, research groups in Germany and the Netherlands have identified mutations in the granulocyte colony-stimulating factor receptor as the cause of severe congenital neutropenia, and have shown that treatment with granulocyte colonystimulating factor can improve survival but also lead to AML.21 Later, HAX1 and JA…”
BackgroundCraddock, C., Slade, D., De Santo, C., Wheat, R., Ferguson, P., Hodgkinson, A., Brock, K., Cavenagh, J., Ingram, W., Dennis, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00889 · Cited by 73 · see citing works
Self-citationFang, D. D., Tang, Q., Kong, Y., Rong, T., Wang, Q., Li, N., Fang, X., Gu, J., Xiong, D., Yin, Y., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00465-5 · Cited by 58 · see citing works
- Authors
- Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., Récher, C., Sandhu, I., Bernal del Castillo, T., Al-Ali, H. K., Martinelli, G., Falantes, J., Noppeney, R., Stone, R. M., Minden, M. D., McIntyre, H., Songer, S., Lucy, L. M., Beach, C. L., & Döhner, H.
- Affiliations
- Hôpital Saint-Louis (FR)
- The University of Melbourne (AU)
- Wroclaw Medical University (PL)
- Medical University of Lodz (PL)
- Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium;
- Samsung Medical Center (KR)
- CancerCare Manitoba (CA)
- National Health Service (GB)
- Princess Margaret Cancer Centre (CA)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Alberta Hospital Edmonton (CA)
- Hospital Central de Asturias, Oviedo, Spain;
- Universitätsklinikum Leipzig, Leipzig, Germany;
- University of Bologna (IT)
- Instituto de Biomedicina de Sevilla (ES)
- Essen University Hospital (DE)
- Dana-Farber Cancer Institute (US)
- Celgene (United States) (US)
- University Hospital Ulm (DE)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-07-16
- Volume
- 126
- Issue
- 3
- Pages
- 291-299
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4504945
- OpenAlex
- W1600365609
- Cited by
- 1,165
- References
- 27
- Citations by year
- 2026: 45 · 2025: 59 · 2024: 80 · 2023: 131 · 2022: 137 · 2021: 153 · 2020: 134 · 2019: 112 · 2018: 99 · 2017: 104 · 2016: 81 · 2015: 29 · 2014: 1
- FWCI
- 81.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- azacitidine, acute myeloid leukemia, elderly patients, newly diagnosed AML, overall survival, induction chemotherapy, supportive care, adverse events, subgroup analysis
- MeSH terms
- Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Blast Crisis, Female, Follow-Up Studies, Humans, International Agencies, Male, Neoplasm Staging, Prognosis, Prospective Studies, Leukemia, Myeloid, Acute, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
